Mid-Year Forum 2025 Social Media Challenge
Winners of the Mid-Year Forum 2025 Social Media Challenge explored their creative side to document their journey to the nation’s capitol. Who won this year’s challenge?
Related Articles
Biomarkers May Predict Ocular Cancer Risk
Conexiant Vision: Delivering trusted clinical content, deep audience engagement, and educational resources for eye care professionals. Discover more through our magazines, newsletters, and events.
4D Molecular Therapeutics receives RMAT designation for 4D-150 for the treatment of diabetic macular edema
4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) to be targeted to the retina…
AI-enhanced imaging offers cellular resolution of RPE in standard eye clinics
Scientists enhance eye imaging with AI, achieving high-resolution views of retinal cells, potentially revolutionizing disease detection and monitoring in clinics.
Journal of Glaucoma
Journal of Glaucoma provides a stimulating forum for discussion of clinical, scientific, and socioeconomic issues of greatest concern to clinicians who care for glaucoma patients.…
Genotypic Distribution and Clinical Correlations in Familial Exudative Vitreoretinopathy: A Single-Center Study
To report the role of wide-angle imaging in detecting suspicious cases of familial exudative vitreoretinopathy (FEVR) in pediatric patients with unexplained vision loss and describe…
Keep Your Eyes Healthy | National Eye Institute
Learn steps you can take to keep your eyes healthy, like getting a dilated eye exam, eating healthy, and staying active.
Ophthalmologists have to accept occupational stress, adapt to it
Medical practice is inherently stressful for the clinician providing the care, the patient receiving it and each of their families.I will focus my comments on…
Phase 1a trial for THN391 yields positive results
Therini Bio reveals promising Phase 1a trial results for THN391, a potential breakthrough treatment for neurodegenerative diseases and retinal conditions.
HORNBILL: A First-in-Human Phase I/IIa Study of the Safety, Tolerability and Early Pharmacodynamics of BI 764524 for Diabetic Macular Ischemia
To report safety and early pharmacodynamic results from a first-in-human trial of intravitreal anti-Semaphorin 3A antibody in participants with diabetic macular ischemia (DMI).
